id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2012-0005,FDA,FDA-2022-E-2012,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:29Z,,0,0,090000648636569b
FDA-2022-E-2012-0004,FDA,FDA-2022-E-2012,Determination of Regulatory Review Period for Purposes of Patent Extension; LYBALV,Notice,Determinations,2023-12-21T05:00:00Z,2023,12,2023-12-21T05:00:00Z,2024-02-21T04:59:59Z,2023-12-21T15:40:37Z,2023-28094,0,0,090000648634e3d6